Seasonal Influenza Vaccine Antigens
In February and September of each year, the World Health Organization (WHO) convenes with its network of advisors to decide on flu vaccine formulations for the northern and southern hemispheres, respectively. To support ongoing vaccine reformulation programmes, The Native Antigen Company develops season-specific antigens to support vaccine and diagnostic manufacturers.
Our Antigens
To support vaccine research and development, The Native Antigen Company has developed Haemagglutinin (HA) and Neuraminidase (NA) antigens for the WHO-recommended egg-based and recombinant vaccine strains. Available in bulk quantities, antigens can be used in a range of applications, including immunoassay development and as immunogens.
Expressed from our proprietary VirtuE™ HEK293 expression system, these antigens exhibit proper glycosylation and folding. Our latest Haemagglutinin antigens feature C-terminal T4 foldon domains, stabilising them in their trimeric conformation to present more native-like conformational epitopes.
For more information on our influenza products, click on the product codes below:
2023 Southern Hemisphere Flu Season Antigens
| | | | | |
| | | | |
|
| | | | |
|
| | | | |
|
| | | | |
|
| | | | |
|
| | | | |
|
| | | | |
|
| | | | | |
| | | | |
|
| | | | |
|
| | | | |
|
| | | | |
|
| | | | |
|
| | | | |
|
| | | | |
|
| | | | |
2022 Southern Hemisphere Flu Season Antigens
2021-2022 Northern Hemisphere Flu Season Antigens
Our Influenza Products
We also offer an extensive range of recombinant HA/NA antigens, native cell lysates and species-specific monoclonal antibodies for established strains.
Our Influenza Services
To support influenza vaccine development, The Native Antigen Company also offers custom services to rapidly develop panels of high quality influenza antigens.
For a bespoke proposal and consultation, please get in touch using the form below